Article
Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2004
Uchida Kazumi, Hayashi Kazuhiko, Kawakami Kazuyuki, Schneider Sylke, Yochim Ji Min, Kuramochi Hidekazu, Takasaki Ken, Danenberg Kathleen D, Danenberg Peter V
Abstract excerpt
Thymidylate synthase (TS), the target enzyme of the fluoropyrimidine class of drugs, has a 28-bp repeat polymorphism in the promoter region that has been associated with response of tumors to 5-fluorouracil-based therapy. Patients homozygous for the double repeat (2R/2R) in the TS gene have an overall better outcome from treatment than patients homozygous for the triple repeat (3R/3R). However, due to loss of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.